Clearwater International Germany advises CoGAP on the sale of the majority of shares to R-Biopharm

Clearwater-Berater

Clearwater International Germany has advised the shareholders of CoGAP GmbH (CoGAP) on the sale of the majority of shares to R-Biopharm AG (R-Biopharm).

Founded in 2009, CoGAP is a highly innovative company specialised in genetic analysis for health optimisation. The company evaluates the latest discoveries within human genetics, and incorporates these into practical applications. CoGAP allows its customers to tailor their health care to their specific needs, and to select the optimal health care recommendations from the breadth of available health care advice.

Headquarted in Germany, R-Biopharm is a leading developer of test solutions for clinical diagnostics, plus food and feed analysis. In both sectors, the R-Biopharm test kits offer high precision and accuracy, key requirements when patient and consumer health is at risk.

The Clearwater International team was led by Managing Partner Dierk Rottmann, and Director Benjamin Bubrowski, with support from Analyst Manuel Erath.

“We are delighted to have advised CoGAP on finding the right strategic partner to help continue its success. CoGAP’s team has strong expertise in the genetic metabolism analysis area, which will enhance the suite of services and products offered by the portfolio business of R-Biopharm.”

Dierk Rottmann, Managing Partner at Clearwater International